臨床泌尿器科61巻9号

2007年08月発行

綜説

肥満と前立腺癌

著者： 金子新¹ 藤山千里¹ 魚住二郎¹

所属機関： ¹佐賀大学医学部泌尿器科学教室

ページ範囲：P.671 - P.678

文献概要

要旨　前立腺癌の増加に伴いその危険因子，予後不良因子の検討が進められている。肥満はメタボリック症候群の概念の登場により，生活習慣病の根源となるものとして特に重要視されている。前立腺癌においても肥満，BMI（body mass index）などと絡めた臨床統計が国内外で多数報告されているが，まだ議論の多いところである。この議論に論拠を与えようとする基礎研究，特に脂肪細胞から分泌される生理活性物質アディポサイトカイン（レプチン，アディポネクチンなど）と前立腺癌の関係を調べた研究が盛んに行われている。肥満と前立腺癌についての現況を，当科での脂肪細胞と前立腺癌細胞株の三次元混合培養による基礎研究も交えて概説する。

参考文献

1）Freedland SJ and Aronson WJ：Examining the relationship between obesity and prostate cancer. Rev Urol 6：73-81, 2004

2）Freedland SJ and Aronson WJ：Obesity and prostate cancer. Urology 65：433-439, 2005

3）Baillargeon J and Rose DP：Obesity, adipokines, and prostate cancer（Review）. Int J Oncol 28：737-745, 2006

4）Freedland SJ, Giovannuci E and Platz EA：Are findings from studies of obesity and prostate cancer really in conflict? Cancer Causes Control 17：5-9, 2006

5）MacLnnis RJ and English DR：Body size and composition and prostate cancer risk：systematic review and meta-regression analysis. Cancer Causes Control 17：989-1003, 2006

6）Mistry T, Digby JE, Desai KM, et al：Obesity and prostate cancer：a role for adipokine. Eur Urol：52：46-53, 2007

7）Baillargeon J, Pollock BH, Kristal AR, et al：The association of body mass index and prostate-specific antigen in a population-based study. Cancer 103：1092-1095, 2005

8）Barqawi AB, Golden BK, O'Donnell C, et al：Observed effect of age and body mass index on total and complexed PSA：analysis from a national screening program. Urology 65：708-712, 2005

9）Werny DM, Thompson T, Saraiya M, et al：Obesity is negatively associated with prostate-specific antigen in U. S. men, 2001-2004. Cancer Epidemiol Biomarkers Prev 16：70-76, 2007

10）Ochiai A, Fritsche HA and Babaian RJ：Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer. Urology 66：819-823, 2005

11）Freedland SJ, Platz EA, Presti JC, et al：Obesity, serum prostate specific antigen and prostate size：implications for prostate cancer detection. J Urol 175：500-504, 2006

12）Zucchetto A, Tavani A, DalMaso L, et al：History of weight and obesity through life and risk of benign prostatic hyperplasia. Int J Obes 29：798-803, 2005

13）Osuna JA, Gomez-Perez R, Arata-Bellabarba G, et al：Relationship between BMI, total testosterone, sex hormone-binding-globlin, leptin, insulin and resistance in obese men. Arch Androl 52：355-361, 2006

14）Rodriguez C, Patel AV, Calle EE, et al：Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 10：345-353, 2001

15）Calle EE, Rodriguez C, Walker-Thurmond K, et al：Over weight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N Engl J Med 348：1625-1638, 2003

16）Freedland SJ, Terris MK, Platz EA, et al：Body mass index as a predictor of prostate cancer：development versus detection on biopsy. Urology 66：108-113, 2005

17）Gong Z, Neuhouser ML, Goodman PJ, et al：Obesity, diabetes, and risk of prostate cancer：results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 15：1977-1983, 2006

18）Rodriguez C, Freedland SJ, Deca A, et al：Body mass index, weight change, and risk of prostate cancer in the cancer prevention study Ⅱ nutrition cohort. Cancer Epidemiol Biomarkers Prev 16：63-69, 2007

19）Kane CJ, Bassett WW, Sadetsky N, et al：Obesity and prostate cancer clinical risk factors at presentation：data from CaPSURE. J Urol 173：732-736, 2005

20）Scale CD, Curtis LH, Norris RD, et al：Relationship between body mass index and prostate cancer screening in the United State. J Urol 177：493-498, 2007

21）Massengill JC, Sun L, Moul JW, et al：Pretreatment total teststerone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 169：1670-1675, 2003

22）Loeb S, Yu X, Nadler RB, et al：Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy? J Urol 177：102-106, 2007

23）D'amico AV, Chen MH, Roehl KA, et al：Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351：125-135, 2004

24）Kurahashi N, Iwasaki M, Sasazuki S, et al：Association of body mass index and height with risk of prostate cancer among middle-aged Japanese men. Brit J Cancer 94：740-742, 2006

25）Furuya Y, Akimoto S, Akakura K, et al：Smoking and obesity in relation to the etiology and disease progression of prostate cancer in Japan. Int J Urol 5：134-137, 1998

26）Presti JC Jr, Lee U, Brooks JD, et al：Lower body mass index is associated with a higher prostate cancer detection rate and less favorable pathological features in a biopsy population. J Urol 171：2199-2202, 2004

27）Porter MP and Stanford JL：Obesity and the risk of prostate cancer. Prostate 62：316-321, 2005

28）Bradbury BD, Wilk JB and Kaye JA：Obesity and the risk of prostate cancer（United States）. Cancer Causes Control 16：637-641, 2005

29）Marks LS, Kojima M, Demarzo A, et al：Prostate cancer in native Japanese and Japanese-American men：effects of dietary differences on prostatic tissue. Urology 64：765-771, 2004

30）Chan JM, Gann PH and Giovannucci EL：Role of diet in prostate cancer development and progressi-on. J Clin Oncol 23：8152-8160, 2005

31）Rodriguez C, McCullough ML, Mondul AM, et al：Meat consumption among black and white men and risk of prostate cancer in the cancer prevention study Ⅱ nutrition cohort. Cancer Epidemiol Biomarkers Prev 15：211-216, 2006

32）Park SY, Murphy SP and Wilkens LR：Fat and meat intake and prostate cancer risk：multiethnic cohort study. Int J Cancer：in press, 2007

33）Bassett WW, Cooperberg MR, Sadetsky N, et al：Impact of obesity on prostate cancer recurrence after radical prostatectomy：data from CaPSURE. Urology 66：1060-1065, 2005

34）Freedland SJ, Aronson WJ, Kane CJ, et al：Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer：a report by the shared equal access regional cancer hospital database study group. J Clin Oncol 22：446-453, 2004

35）Freedland SJ, Terris MK, Presti JC Jr, et al：Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. J Urol 172：520-524, 2004

36）Strom SS, Wang X, Pettaway CA, et al：Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res 11：6889-6894, 2005

37）Siddiqui SA, Inman BA, Sengupta S, et al：Obesity and survival after radical prostatectomy. Cancer 107：521-529, 2006

38）Strom SS, Kamat AM, Gruschkus SK, et al：Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer 107：631-639, 2006

39）Smith MR：Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Clin Cancer Res 13：241-245, 2007

40）下村伊一郎，船橋　徹，木原進士，他：生活習慣病の主役　アディポサイトカイン．特集　脂肪細胞の多彩な機能と肥満症のメカニズム．実験医学 20：1762-1767，2002

41）Onuma M, Bub JD, Rummel TL, et al：Prostate cancer cell-adipocyte interaction：leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem 278：42660-42667, 2003

42）Frankenberry KA, Somasunder P, McFadden DW, et al：Leptin induces cell migration and expression of growth factors in human prostate cancer cells. Am J Surg 188：560-565, 2004

43）Somasunder P, Frankenberry KA, Skinner H, et al：Prostate cancer cell proliferation is influenced by leptin. J Surg Res 118：71-82, 2004

44）Stattin P, Söderberg S, Hallmans G, et al：Leptin is associated with increased prostate cancer risk：a nested case-referent study. J Clin Endocrinol Metab 86：1341-1345, 2001

45）Ribeiro R, Vasconcelos A, Costa S, et al：Overexpressing leptin genetic polymorphism（-2548G/A）is associated with susceptibility to prostate cancer and risk of advanced disease. Prostate 59：268-274, 2004

46）Bub JD, Miyazaki T and Iwamoto Y：Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun 340：1158-1166, 2006

47）Mistry T, Digby JE, Chen J, et al：The regulation of adiponectin recepyors in human prostate cancer cell lines. Biochem Biophys Res Commun 348：832-838, 2006

48）Yamauchi T, Kamon J, Ito Y, et al：Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423：762-769, 2003

-terminal kinase and inhibits signal transducer and activator of transcription 3. Biochem Biophys Res Commun 333：79-87, 2005

50）Freedland SJ, Sokoll LJ, Platz EA, et al：Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. J Urol 174：1266-1270, 2005

51）Micke P and Östman A：Tumour-stroma interaction：cancer-associated fibroblasts as nobel targets in anti-cancer therapy? Lung Cancer 45（Suppl）：S163-S175, 2004

52）Orimo A, Gupta PB, Sgroi DC, et al：Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121：335-348, 2005

53）Tokuda Y, Satoh Y, Fujiyama C, et al：Prostate cancer cell growth is modulated by adipocyte-cancer cell interaction. BJU Int 91：716-720, 2003

54）金子新，佐藤勇司，藤山千里，他：コラーゲンゲル三次元混合培養による前立腺癌細胞に対する脂肪細胞の影響の検討．西日泌尿 69：171-175，2007

55）McMenamin ME, Soung P, Perera S, et al：Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59：4291-4296, 1999

56）Malik SN, Brattain M, Ghosh PM, et al：Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8：1168-1171, 2002

57）Gioeli D, Mandell JW, Petroni GR, et al：Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59：279-284, 1999

58）Kuniyasu H, Troncoso P, Johnston D, et al：Relative expression of Type Ⅳ collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 6：2295-2308, 2000